Top

Published in:

Open Access 28-02-2024 | Pompe Disease | Original Communication

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)

Authors: Benedikt Schoser, Priya S. Kishnani, Drago Bratkovic, Barry J. Byrne, Kristl G. Claeys, Jordi Díaz-Manera, Pascal Laforêt, Mark Roberts, Antonio Toscano, Ans T. van der Ploeg, Jeff Castelli, Mitchell Goldman, Fred Holdbrook, Sheela Sitaraman Das, Yasmine Wasfi, Tahseen Mozaffar, the ATB200-07 Study Group

Published in: Journal of Neurology | Issue 5/2024

Abstract

The phase III double-blind PROPEL study compared the novel two-component therapy cipaglucosidase alfa + miglustat (cipa + mig) with alglucosidase alfa + placebo (alg + pbo) in adults with late-onset Pompe disease (LOPD). This ongoing open-label extension (OLE; NCT04138277) evaluates long-term safety and efficacy of cipa + mig. Outcomes include 6-min walk distance (6MWD), forced vital capacity (FVC), creatine kinase (CK) and hexose tetrasaccharide (Hex4) levels, patient-reported outcomes and safety. Data are reported as change from PROPEL baseline to OLE week 52 (104 weeks post-PROPEL baseline). Of 118 patients treated in the OLE, 81 continued cipa + mig treatment from PROPEL (cipa + mig group; 61 enzyme replacement therapy [ERT] experienced prior to PROPEL; 20 ERT naïve) and 37 switched from alg + pbo to cipa + mig (switch group; 29 ERT experienced; 8 ERT naive). Mean (standard deviation [SD]) change in % predicted 6MWD from baseline to week 104 was + 3.1 (8.1) for cipa + mig and − 0.5 (7.8) for the ERT-experienced switch group, and + 8.6 (8.6) for cipa + mig and + 8.9 (11.7) for the ERT-naïve switch group. Mean (SD) change in % predicted FVC was − 0.6 (7.5) for cipa + mig and − 3.8 (6.2) for the ERT-experienced switch group, and − 4.8 (6.5) and − 3.1 (6.7), respectively, in ERT-naïve patients. CK and Hex4 levels improved in both treatment groups by week 104 with cipa + mig treatment. Three patients discontinued the OLE due to infusion-associated reactions. No new safety signals were identified. Cipa + mig treatment up to 104 weeks was associated with overall maintained improvements (6MWD, biomarkers) or stabilization (FVC) from baseline with continued durability, and was well tolerated, supporting long-term benefits for patients with LOPD.

Trial registration number: NCT04138277; trial start date: December 18, 2019.

Available only for authorised users

Cabello J, Marsden D (2017) Pompe disease: clinical perspectives. Orphan Drugs Res Rev 7:1–10. https://doi.org/10.2147/odrr.S69109CrossRef

Park KS (2021) Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database. Mol Genet Metab Rep 27:100734. https://doi.org/10.1016/j.ymgmr.2021.100734CrossRefPubMedPubMedCentral

Nino MY, In’t Groen SLM, Bergsma AJ et al (2019) Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat 40:1954–1967. https://doi.org/10.1002/humu.23854CrossRefPubMedPubMedCentral

Raben N, Wong A, Ralston E et al (2012) Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet 160C:13–21. https://doi.org/10.1002/ajmg.c.31317CrossRefPubMed

Cupler EJ, Berger KI, Leshner RT et al (2012) Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 45:319–333. https://doi.org/10.1002/mus.22329CrossRefPubMed

Kishnani PS, Hwu WL, Mandel H et al (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676. https://doi.org/10.1016/j.jpeds.2005.11.033CrossRefPubMed

Kishnani PS, Howell RR (2004) Pompe disease in infants and children. J Pediatr 144:S35-43. https://doi.org/10.1016/j.jpeds.2004.01.053CrossRefPubMed

van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372:1342–1353. https://doi.org/10.1016/S0140-6736(08)61555-XCrossRefPubMed

Kishnani PS, Steiner RD, Bali D et al (2006) Pompe disease diagnosis and management guideline. Genet Med 8:267–288. https://doi.org/10.1097/01.gim.0000218152.87434.f3CrossRefPubMedPubMedCentral

10.

Toscano A, Rodolico C, Musumeci O (2019) Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med 7:284. https://doi.org/10.21037/atm.2019.07.24CrossRefPubMedPubMedCentral

11.

Tarnopolsky M, Katzberg H, Petrof BJ et al (2016) Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel. Can J Neurol Sci 43:472–485. https://doi.org/10.1017/cjn.2016.37CrossRefPubMed

12.

van der Ploeg AT, Kruijshaar ME, Toscano A et al (2017) European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol 24:768-e31. https://doi.org/10.1111/ene.13285CrossRefPubMed

13.

European Medicines Agency (2014) Committee for medicinal products for human use (CHMP) opinion on Myozyme. Available from https://www.ema.europa.eu/en/medicines/human/EPAR/myozyme. Accessed 31 Jan 2024

14.

van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–406. https://doi.org/10.1056/NEJMoa0909859CrossRefPubMed

15.

Gutschmidt K, Musumeci O, Diaz-Manera J et al (2021) STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa. J Neurol 268:2482–2492. https://doi.org/10.1007/s00415-021-10409-9CrossRefPubMedPubMedCentral

16.

Harlaar L, Hogrel JY, Perniconi B et al (2019) Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology 93:e1756–e1767. https://doi.org/10.1212/WNL.0000000000008441CrossRefPubMedPubMedCentral

17.

Schoser B, Stewart A, Kanters S et al (2017) Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol 264:621–630. https://doi.org/10.1007/s00415-016-8219-8CrossRefPubMed

18.

Semplicini C, De Antonio M, Taouagh N et al (2020) Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry. J Inherit Metab Dis 43:1219–1231. https://doi.org/10.1002/jimd.12272CrossRefPubMed

19.

Do HV, Khanna R, Gotschall R (2019) Challenges in treating Pompe disease: an industry perspective. Ann Transl Med 7:291. https://doi.org/10.21037/atm.2019.04.15CrossRefPubMedPubMedCentral

20.

Xu S, Lun Y, Frascella M et al (2019) Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight 4:e125358. https://doi.org/10.1172/jci.insight.125358CrossRefPubMedPubMedCentral

21.

Selvan N, Mehta N, Venkateswaran S et al (2021) Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase. J Biol Chem 296:100769. https://doi.org/10.1016/j.jbc.2021.100769CrossRefPubMedPubMedCentral

22.

Johnson FK, Kang J, Mondick J et al (2022) Mechanism of action, plasma total GAA protein profiles and PK/PD relationships differ between cipaglucosidase alfa/miglustat and alglucosidase alfa in patients with late-onset Pompe disease. In: World symposium, San Diego, CA, USA

23.

Blair HA (2023) Cipaglucosidase alfa: first approval. Drugs 83:739–745. https://doi.org/10.1007/s40265-023-01886-5CrossRefPubMedPubMedCentral

24.

Meena NK, Ralston E, Raben N et al (2020) Enzyme replacement therapy can reverse pathogenic cascade in Pompe disease. Mol Ther Methods Clin Dev 18:199–214. https://doi.org/10.1016/j.omtm.2020.05.026CrossRefPubMedPubMedCentral

25.

Schoser B, Roberts M, Byrne BJ et al (2021) Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol 20:1027–1037. https://doi.org/10.1016/s1474-4422(21)00331-8CrossRefPubMed

26.

Byrne BJ, Kishnani PS, Case LE et al (2011) Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab 103:1–11. https://doi.org/10.1016/j.ymgme.2011.02.004CrossRefPubMed

27.

Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–7. https://doi.org/10.1164/ajrccm.158.5.9710086CrossRefPubMed

28.

Quanjer PH, Stanojevic S, Cole TJ et al (2012) Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 40:1324–43. https://doi.org/10.1183/09031936.00080312CrossRefPubMedPubMedCentral

29.

Gungor D, de Vries JM, Hop WC et al (2011) Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 6:34. https://doi.org/10.1186/1750-1172-6-34CrossRefPubMedPubMedCentral

30.

Winkel LP, Hagemans ML, van Doorn PA et al (2005) The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 252:875–84. https://doi.org/10.1007/s00415-005-0922-9CrossRefPubMed

31.

Meena NK, Raben N (2020) Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules 10:1339. https://doi.org/10.3390/biom10091339CrossRefPubMedPubMedCentral

32.

Puertollano R, Raben N (2021) New therapies for Pompe disease: are we closer to a cure? Lancet Neurol 20:973–975. https://doi.org/10.1016/S1474-4422(21)00358-6CrossRefPubMed

33.

National Library of Medicine (2023) First-in-human study to evaluate safety, tolerability, and PK of intravenous ATB200 alone and when co-administered with oral AT2221. 2023 [cited 2023 24 Feb]. Available from https://clinicaltrials.gov/ct2/show/NCT02675465. Accessed 31 Jan 2024

34.

Byrne BJ, Schoser B, Kishnani PS et al (2023) Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). J Neurol. https://doi.org/10.1007/s00415-023-12096-0CrossRefPubMedPubMedCentral

35.

An Y, Young SP, Kishnani PS et al (2005) Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85:247–254. https://doi.org/10.1016/j.ymgme.2005.03.010CrossRefPubMed

36.

Brancaccio P, Lippi G, Maffulli N (2010) Biochemical markers of muscular damage. Clin Chem Lab Med 48:757–67. https://doi.org/10.1515/cclm.2010.179CrossRefPubMed

37.

Khan AA, Case LE, Herbert M et al (2020) Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. Genet Med 22:898–907. https://doi.org/10.1038/s41436-019-0738-0CrossRefPubMedPubMedCentral

38.

Harfouche M, Kishnani PS, Krusinska E et al (2020) Use of the patient-reported outcomes measurement information system (PROMIS(R)) to assess late-onset Pompe disease severity. J Patient Rep Outcomes 4:83. https://doi.org/10.1186/s41687-020-00245-2CrossRefPubMedPubMedCentral

39.

Kishnani PS, Díaz-Manera J, Kushlaf H et al (2023) Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks of treatment during the COMET trial. Mol Gen Metab 138:107185. https://doi.org/10.1016/j.ymgme.2022.107185CrossRef

Title: 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)
Authors: Benedikt Schoser
Priya S. Kishnani
Drago Bratkovic
Barry J. Byrne
Kristl G. Claeys
Jordi Díaz-Manera
Pascal Laforêt
Mark Roberts
Antonio Toscano
Ans T. van der Ploeg
Jeff Castelli
Mitchell Goldman
Fred Holdbrook
Sheela Sitaraman Das
Yasmine Wasfi
Tahseen Mozaffar
the ATB200-07 Study Group
Publication date: 28-02-2024
Publisher: Springer Berlin Heidelberg
Keyword: Pompe Disease
Published in: Journal of Neurology / Issue 5/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-024-12236-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Amyloid antibody therapy for early-stage Alzheimer’s disease: a critical review of three recent trials

POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis

The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)

The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis

Progression rate of radiation-induced carotid stenosis in head and neck cancer survivors after statin treatment: a retrospective cohort study

Improvement of fatigue in generalised myasthenia gravis with zilucoplan